Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 180.99 Billion KRW | 34.33% |
| 2022 | 134.73 Billion KRW | 5330.51% |
| 2021 | 2.48 Billion KRW | -16.48% |
| 2020 | 2.97 Billion KRW | -23.1% |
| 2019 | 3.86 Billion KRW | -89.84% |
| 2018 | 38 Billion KRW | -26.41% |
| 2017 | 51.65 Billion KRW | 39.44% |
| 2016 | 37.04 Billion KRW | 327.6% |
| 2015 | 8.66 Billion KRW | -38.37% |
| 2014 | 14.05 Billion KRW | 31.31% |
| 2013 | 10.7 Billion KRW | -22.24% |
| 2012 | 13.76 Billion KRW | -56.36% |
| 2011 | 31.54 Billion KRW | 43.23% |
| 2010 | 22.02 Billion KRW | -10.08% |
| 2009 | 24.49 Billion KRW | 300.71% |
| 2008 | 6.11 Billion KRW | -65.15% |
| 2007 | 17.53 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 166.51 Billion KRW | -9.46% |
| 2024 Q1 | 183.91 Billion KRW | 1.61% |
| 2023 Q3 | 142 Billion KRW | 36.41% |
| 2023 Q2 | 104.09 Billion KRW | -25.3% |
| 2023 FY | 180.99 Billion KRW | 34.33% |
| 2023 Q1 | 139.34 Billion KRW | 3.42% |
| 2023 Q4 | 180.99 Billion KRW | 27.46% |
| 2022 Q1 | 2.49 Billion KRW | 0.55% |
| 2022 FY | 134.73 Billion KRW | 5330.51% |
| 2022 Q4 | 134.73 Billion KRW | 1359.53% |
| 2022 Q3 | 9.23 Billion KRW | 237.84% |
| 2022 Q2 | 2.73 Billion KRW | 9.53% |
| 2021 FY | 2.48 Billion KRW | -16.48% |
| 2021 Q4 | 2.48 Billion KRW | 21.04% |
| 2021 Q1 | 2.6 Billion KRW | -12.38% |
| 2021 Q2 | 2.38 Billion KRW | -8.3% |
| 2021 Q3 | 2.04 Billion KRW | -14.12% |
| 2020 FY | 2.97 Billion KRW | -23.1% |
| 2020 Q4 | 2.97 Billion KRW | -24.63% |
| 2020 Q3 | 3.94 Billion KRW | -19.66% |
| 2020 Q1 | 4.36 Billion KRW | 12.9% |
| 2020 Q2 | 4.9 Billion KRW | 12.48% |
| 2019 Q2 | 31.36 Billion KRW | 3.4% |
| 2019 Q4 | 3.86 Billion KRW | -62.61% |
| 2019 FY | 3.86 Billion KRW | -89.84% |
| 2019 Q1 | 30.33 Billion KRW | -20.2% |
| 2019 Q3 | 10.33 Billion KRW | -67.06% |
| 2018 Q2 | 36.75 Billion KRW | -19.55% |
| 2018 Q3 | 37.15 Billion KRW | 1.11% |
| 2018 FY | 38 Billion KRW | -26.41% |
| 2018 Q4 | 38 Billion KRW | 2.29% |
| 2018 Q1 | 45.67 Billion KRW | -11.56% |
| 2017 Q4 | 51.65 Billion KRW | -14.28% |
| 2017 FY | 51.65 Billion KRW | 39.44% |
| 2017 Q3 | 60.25 Billion KRW | 54.57% |
| 2017 Q2 | 38.98 Billion KRW | 1.88% |
| 2017 Q1 | 38.26 Billion KRW | 3.3% |
| 2016 FY | 37.04 Billion KRW | 327.6% |
| 2016 Q2 | 34.47 Billion KRW | 64.11% |
| 2016 Q3 | 35.69 Billion KRW | 3.55% |
| 2016 Q4 | 37.04 Billion KRW | 3.77% |
| 2016 Q1 | 21 Billion KRW | 142.49% |
| 2015 Q3 | 8.49 Billion KRW | 3.35% |
| 2015 Q4 | 8.66 Billion KRW | 2.0% |
| 2015 Q1 | 14.56 Billion KRW | 3.63% |
| 2015 Q2 | 8.21 Billion KRW | -43.59% |
| 2015 FY | 8.66 Billion KRW | -38.37% |
| 2014 Q2 | 17.14 Billion KRW | -19.48% |
| 2014 Q1 | 21.29 Billion KRW | 98.89% |
| 2014 FY | 14.05 Billion KRW | 31.31% |
| 2014 Q4 | 14.05 Billion KRW | -15.54% |
| 2014 Q3 | 16.64 Billion KRW | -2.91% |
| 2013 Q4 | 10.7 Billion KRW | -3.19% |
| 2013 FY | 10.7 Billion KRW | -22.24% |
| 2013 Q3 | 11.05 Billion KRW | 2.45% |
| 2013 Q2 | 10.79 Billion KRW | 7.88% |
| 2013 Q1 | 10 Billion KRW | -27.32% |
| 2012 FY | 13.76 Billion KRW | -56.36% |
| 2012 Q4 | 13.76 Billion KRW | 0.0% |
| 2012 Q1 | 25.71 Billion KRW | 0.0% |
| 2011 Q1 | 18.67 Billion KRW | 0.0% |
| 2011 FY | 31.54 Billion KRW | 43.23% |
| 2011 Q3 | 27.25 Billion KRW | 47.6% |
| 2011 Q2 | 18.46 Billion KRW | -1.11% |
| 2010 Q1 | 20.37 Billion KRW | -0.06% |
| 2010 FY | 22.02 Billion KRW | -10.08% |
| 2010 Q2 | 13.53 Billion KRW | -33.56% |
| 2009 Q4 | 20.39 Billion KRW | 0.0% |
| 2009 FY | 24.49 Billion KRW | 300.71% |
| 2009 Q2 | 14.16 Billion KRW | 265.68% |
| 2009 Q1 | 3.87 Billion KRW | 0.15% |
| 2008 FY | 6.11 Billion KRW | -65.15% |
| 2008 Q2 | 14.71 Billion KRW | -21.52% |
| 2008 Q1 | 18.75 Billion KRW | 4.65% |
| 2008 Q4 | 3.86 Billion KRW | 0.0% |
| 2007 Q1 | 11.84 Billion KRW | 0.0% |
| 2007 Q2 | 11.75 Billion KRW | -0.83% |
| 2007 FY | 17.53 Billion KRW | 0.0% |
| 2007 Q4 | 17.92 Billion KRW | 2.22% |
| 2007 Q3 | 17.53 Billion KRW | 49.24% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -359.301% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 73.84% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 52.626% |
| HANDOK Inc. | 300.01 Billion KRW | 39.67% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -490.297% |
| Yuhan Corporation | 230.07 Billion KRW | 21.33% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 55.497% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -30294.9% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 68.405% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -13925.04% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -112.538% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -318.27% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -100.036% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -582.157% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -359.301% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -75909.047% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 19.576% |
| JW Holdings Corporation | 554.58 Billion KRW | 67.364% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 16.913% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 17.64% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -6.294% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -292.181% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -361.67% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | -2.91% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -113.024% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -359.301% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 23.19% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 61.464% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -6.294% |
| Yuhan Corporation | 230.07 Billion KRW | 21.33% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | -4.604% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -170.622% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 61.314% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -6.294% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -52.562% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -348.69% |
| CKD Bio Corp. | 146.92 Billion KRW | -23.189% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -23.929% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -275.082% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -28537.657% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -292.181% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 61.328% |
| Boryung Corporation | 204.21 Billion KRW | 11.37% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -127.994% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -112.538% |
| JW Lifescience Corporation | 46.31 Billion KRW | -290.815% |